Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319198 · ClinicalTrials.gov registry record · Phase 4
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
A Phase 4 study of Metastatic Solid Tumors, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 20
- Study locations
NCT04319198 is a Phase 4 study of Metastatic Solid Tumors that has completed, run by Gilead Sciences. The registered enrollment target is 25 participants, below the 205-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04319198, a Phase 4 study of Metastatic Solid Tumors, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
Conditions Studied
Interventions
- DRUG Sacituzumab Govitecan-hiy
Study Locations (20)
Texas
- Next Oncology - Austin
- Oncology Consultants,P.A. - Houston
- The University of Texas M.D. Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Other
- Institut Jules Bordet - Brussels
- CHU UCL NAMUR - Sainte Elisabeth - Namur
- Institut Bergonie - Bordeaux
- Centre Leon Berard - Lyon
Florida
- Florida Cancer Specialists & Research Institute - Fort Myers
- Baptist Health - Miami Cancer Institute - Miami
Illinois
- Illinois Cancer Specialists - Arlington Heights
- University of Chicago - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
California
- University of California San Francisco - San Francisco
Colorado
- Rocky Mountain Cancer Center - Aurora
Delaware
- Christiana Care Health Services, Christiana Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04319198
The ClinicalTrials.gov registry entry for NCT04319198 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (88% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab Govitecan-hiy is the first listed.
NCT04319198 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT04319198 about?
NCT04319198 is a clinical study titled "Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy". The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
What is the current status of trial NCT04319198?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2020-08-04. Estimated completion is 2024-10-18.
What conditions does trial NCT04319198 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors.
What interventions are being tested in trial NCT04319198?
The interventions under investigation include: Sacituzumab Govitecan-hiy (DRUG).
Who is sponsoring clinical trial NCT04319198?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04319198 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
RECRUITING · Phase 2
-
SLV-324 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.